Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.
The findings of a recent study suggest that vaginal seeding is safe and may normalize the gut microbiota in infants born by C-section.
Microbiomepost discussed with Herbert Tilg, Medizinische Universitat Innsbruck, Austria, about the importance of gut microbiome for intestinal and not intestinal health.
Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
IgA can modulate the exposure and immune response to commensal microbes, and its levels determine the severity of immune dysregulation and clinical symptoms in people with IgA deficiency.
Christophe Roca, Head of Pilot Department at Sacco System, talks about development and GMP production of Live Biotherapeutics for all applications.
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
With all aspects of LBPs covered in the summit, the 8th Microbiome Movement Summit in Boston became the hub for sharing the latest insights in LBP research and development.
The findings of a new study suggest that the new nanomedicine approach can improve the delivery of TNF-α-siRNA in people with IBD.
Airway dysbiosis was associated with a lung function decline in COPD patients and it might contribute to this phenotype through metabolic interaction with host pathophysiological processes.
